Ville Vartiainen

Dr. Ville Vartiainen

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CLChang Li
Chang Li
VRVeronika Rezov
Veronika Rezov
EJEmmi Joensuu
Emmi Joensuu
VVVille Vartiainen
Ville Vartiainen
MRMikko Rönty
Mikko Rönty
KKKatri Koli
Katri Koli
Malignant mesothelioma is an aggressive cancer with poor prognosis. It is characterized by prominent extracellular matrix, mesenchymal tumor cell phenotypes and chemoresistance. In this study, the ability of pirfenidone to alter mesothelioma cell proliferation and migration as well as mesothelioma tumor microenvironment was evaluated. Pirfenidone is an anti-fibrotic drug used in the treatment of idiopathic pulmonary fibrosis and has also anti-proliferative activities. Mesothelioma cell proliferation was decreased by pirfenidone alone or in combination with cisplatin. Pirfenidone also decreased significantly Transwell migration/invasion and 3D collagen invasion. This was associated with increased BMP pathway activity, decreasedGREM1expression and downregulation of MAPK/ERK and AKT/mTOR signaling. The canonical Smad-mediated TGF-β signaling was not affected by pirfenidone. However, pirfenidone blocked TGF-β induced upregulation of ERK and AKT pathways. Treatment of mice harboring mesothelioma xenografts with pirfenidone alone did not reduce tumor proliferationin vivo. However, pirfenidone modified the tumor microenvironment by reducing the expression of extracellular matrix associated genes. In addition,GREM1expression was downregulated by pirfenidonein vivo. By reducing two major upregulated pathways in mesothelioma and by targeting tumor cells and the microenvironment pirfenidone may present a novel anti-fibrotic and anti-cancer adjuvant therapy for mesothelioma.


1 August 2024 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
VVVille Vartiainen
Ville Vartiainen
AWAshley A Woodcock
Ashley A Woodcock
AWAlex Wilkinson
Alex Wilkinson
Christer JansonChrister Janson
Christer Janson
UBUnnur Björnsdóttir
Unnur Björnsdóttir
LLLauri Lehtimäki
Lauri Lehtimäki
Introduction: Both physicians and patients are increasingly aware of the environmental impacts of medication. The shift of treatment paradigm towards MART-treatment (Maintenance and Reliever Therapy) in asthma affects the treatment-related emissions. The carbon footprint of inhaled medication is also tied to the type of the device used. Today the most commonly used propellant-containing pressurised metered-dose inhalers (pMDIs) have a carbon footprint typically 20–40-fold higher than propellant-free dry powder inhalers (DPIs) and soft mist inhalers. Methods: We analysed the carbon footprint of inhaled medications in Europe using published life cycle analyses of marketed inhalers and comprehensive 2020 European sales data. In addition, we give an estimate on treatment-related emissions of different treatment regimens on Global Initiative for Asthma (GINA) step 2. Results: There is potential to reduce the carbon footprint of inhaled medications by 85% if DPIs are preferred over pMDIs. Emissions from pMDIs in the EU were estimated to be 4.0 megatons of carbon dioxide equivalent (MT CO2e) and this could be reduced to 0.6 MT CO2e if DPIs were used instead. In the treatment of moderate asthma with DPI, an as-needed combination of inhaled corticosteroid and long-acting beta-agonist in a single inhaler had a substantially lower annual carbon footprint (0.8 kg CO2e) than the more traditional maintenance therapy with an inhaled corticosteroid alone with as-needed short-acting beta-agonist (2.9 kg CO2e). Discussion: There has been an urgent call for healthcare to reduce its carbon footprint for appropriate patients with asthma and chronic obstructive pulmonary disease (COPD), changing to non-propellant inhalers can reduce the carbon footprint of their treatment by almost 20-fold.

1 April 2021 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
RJRain Jõgi
Rain Jõgi
LMLeena Mattila
Leena Mattila
MVMikko Vahteristo
Mikko Vahteristo
ATAino Takala
Aino Takala
SLSatu Lähelmä
Satu Lähelmä
ALAri Lindqvist
Ari Lindqvist
Introduction: Achieving correct inhalation technique through an inhaler to ensure effective drug delivery is key to managing symptoms in patients with chronic obstructive pulmonary disease (COPD). However, many patients struggle to use their inhalers correctly, with the resultant reduction in therapeutic benefit. Consequently, appropriate inhaler choice is important to maximize clinical benefit. The primary objective of this study was to characterize inspiratory flow parameters across two Easyhaler® inhalers and the HandiHaler® inhaler in patients with COPD and healthy volunteers. Methods: In this randomized, open-label, crossover study, subjects (100 patients with COPD; 100 healthy volunteers) were trained to perform inhalations of placebo powder via two variants of Easyhaler and placebo capsules via the HandiHaler inhalers. Subjects then performed three placebo inhalations through each inhaler in a random sequence. Inspiratory flow parameters were assessed, including peak inspiratory flow (PIF), for each inhaler. A parallel sub-study was conducted in patients with COPD from the main study to assess correct use of the inhalers, patient’s preference, ability to learn to use the inhalers, and the feasibility of the In-Check Dial device to measure PIF values. Results: Mean PIF rates and inspiratory volumes through the three inhalers were similar between patients with COPD and healthy volunteers, and all subjects achieved the 30 L/min PIF required for effective use of Easyhaler. Almost 70% of the 88 patients enrolled in the sub-study used the Easyhaler and HandiHaler inhalers without errors. The Easyhaler was preferred by 51% of patients, while 25% favored the HandiHaler. Teaching the use of both inhalers to almost 70% of patients was very easy. The In-Check Dial PIF values and those obtained via spirometry were strongly correlated (p< 0.0001) for all three inhalers. Conclusion: The respiratory performance of patients with COPD does not appear to be a limiting factor in the use of Easyhaler.

26 February 2023 in Expert Opinion on Drug Delivery
Verified
Journal Article
Open access
VVVille Vartiainen
Ville Vartiainen
FLFEDERICO LAVORINI
FEDERICO LAVORINI
AMAnna C Murphy
Anna C Murphy
KRKlaus F Rabe
Klaus F Rabe
There has been an active discussion on the sustainability of inhaler therapy in respiratory diseases and it has cast a shadow on pMDIs which rely on propellant with high global warming potential (G...

1 May 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
VVVille Vartiainen
Ville Vartiainen
Luis M. BimboLuis M. Bimbo
Luis M. Bimbo
Jouni HirvonenJouni Hirvonen
Jouni Hirvonen
EKEsko I. Kauppinen
Esko I. Kauppinen
JRJanne Raula
Janne Raula